Clinical Trials, Technology

Cost-Effective Way to De-Risk Biomarker Clinical Trials

By Ce3

This free white paper discusses the early development considerations when considering cost-effective ways to de-risk biomarker clinical trials. Using a diagnostic assay during early drug development decreases enrolment costs and shortens trial timelines by focusing on target patient population. Trial failure is also minimised as the right patient, treatment, time and dose are identified. In addition, drug and assay development timelines are coordinated such as for applications for accelerated approval or breakthrough designation. However, the assay takes time to develop, so coordination is key. It also requires an additional investment in the early development phase. Download this white paper to find out more.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.